Two patients with bleeding diathesis had dysfunctional platelet P2Y 12 R for ADP, due to homozygous His187Gln mutation.
Introduction
P2Y 12 , which maps to chromosome 3q21-q25, is one of the two receptors for adenosine diphosphate (ADP) that are expressed by platelets.
1,2 It is a Gi-coupled receptor that plays an important role both in hemostasis and thrombosis. This role is demonstrated by the observations that patients with inherited defects of the receptor display a bleeding The study of molecular abnormalities associated with inherited qualitative defects of the P2Y 12 R protein is useful to unravel structure-function relationships of the receptor.
Mutations in the region that spans the transition between trans-membrane helix (TM) 6
and extracellular loop (EL) 3 are associated with receptor dysfunction despite normal ligand binding, suggesting that this region of the molecule plays a role in signal
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2,7-9 A heterozygous mutation, predicting a lysine to glutamate (p.Lys174Glu) substitution in the P2Y 12 R, was identified in one patient with reduced and reversible aggregation in response to ADP and an approximate 50% reduction in binding of agonist radioligand [ 3 H]2-MeSADP. 10 Considering that Lys174 is situated in the EL2 of the P2Y 12 R, adjacent to Cys175, which may be important for the integrity of the ADP binding site on the receptor, 11 and that a hemagglutinin-tagged p.Lys174Glu P2Y 12 R variant showed surface expression in Chinese hamster ovary cells, it was hypothesized that the p.Lys174Glu mutation inhibits ADP binding to the receptor. Recently reported crystallographic data 12, 13 do not show a direct involvement of Lys174 in agonist binding but rather a role in stabilizing the receptor conformation through inter-residues ionic interactions and/or in affecting the approach of the ligand to its binding site. In one patient, with no personal history of abnormal bleeding, reduced expression of P2Y 12 
Methods

Patients and controls
The proband (III-7 in Figure 1 ) is a 45 year old man living in Germany, who belongs to a
For personal use only. on October 28, 2017 . by guest www.bloodjournal.org From large family of Turkish origin (Figure 1 ). He presented with recurrent epistaxis, postoperative bleeding after tooth extraction, thyroid explantation due to thyroid hyperplasia, and spleen explantation, consequent to spleen rupture in a car accident. He had normal platelet count (307x10 9 /L), screening coagulation tests (prothrombin time and activated partial thromboplastin time) and plasma levels of von Willebrand factor antigen and ristocetin cofactor activity. Serum thromboxane B 2 levels and the platelet contents of serotonin, ADP, ATP and fibrinogen were normal. Blood samples for genetic studies were available from his parents, who are first cousins, and 9 relatives (2 grandparents and 7 brothers and sisters), with negative, mild or severe bleeding history. The 57 year old brother, with severe bleeding history (III-1, Figure 1 ), also provided blood samples for platelet function studies.
A total of 36 healthy subjects, with no personal history of abnormal bleeding, were also studied. All subjects gave consent to the study.
Materials
[ 3 H]PSB-0413 was prepared by catalytic hydrogenation with tritium gas (GE, Healthcare, Buckinghamshire, UK) of the propargyl precursor PSB-0412 as described. 15 ADP, 2MeSADP, collagen, the thromboxane/prostaglandin endoperoxide analogue 9,11-dideoxy-11,9-epoxymethano-prostaglandin F 2 (U46619), thrombin receptor activating peptide 6 (TRAP-6), prostaglandin (PG) E 1 , PGI 2, were from Sigma (St. Louis, MO, USA).
Apyrase was purified from potatoes. 17 Commercial preparations of luciferin/luciferase reagent were used to measure the platelet ATP and ADP contents (ATP Assay Kit, BioOrbit Oy, Turku, Finland), and platelet secretion concurrently with platelet aggregation (Chronolume, Chrono-log Corp, Havertown, PA, USA 21 with the exception that 500 nmol/L PGI 2 was added during the first and second wash. Platelet counts in washed platelet suspensions were adjusted to 3x10 11 /L.
Studies of Platelet Aggregation and Secretion
The first screening of platelet aggregation in patient III-7 was performed in Freiburg platelets. 15 Nonspecific binding was defined in the presence of 1 mM ADP. Washed platelets were incubated with the ligand at 37°C for 5 min; then bound and free radioactivity was separated by filtration through Whatman GF/B glass-fiber filters. Filters were then washed with 5x2 ml of ice cold washing buffer (Tris HCl 50 mM pH 7.5, EDTA 1 mM, MgCl 2 5 mM, NaCl 100 mM). Filter-bound radioactivity was counted in 2 ml liquid scintillation counter. Assays were performed in triplicate in 3 independent experiments, 2
in III-7 and 1 in III-1.
Competition experiments were performed in triplicate using a fixed concentration of 
VASP phosphorylation analysis
The VASP phosphorylation analysis was performed immediately after blood collection, 
Genetic Studies
Genomic DNA was isolated from peripheral blood lymphocytes using standard procedures.
The entire coding sequence of the P2Y 12 R gene was amplified by a single polymerase chain reaction (PCR). PCR was performed using the primers (forward) 
Molecular Modeling of the P2Y 12 R
The recently resolved crystallographic structures of the human P2Y 12 R in complex with the antagonist AZD1283 (PDB ID: 4NTJ) 12 and with the full agonist 2MeSADP (PDB ID: 4PXZ) 13 were used in this study. Models of the P2Y 12 R Gln-187 variant, based on the agonist-bound P2Y 12 R structure, were built by mutating His187 to Gln directly in the structure and then by modifying its conformation by selecting five different, suitable rotamers.
All P2Y 12 R structures were prepared using the Protein Preparation Wizard tool 22 implemented in the Schrödinger suite, 23 adding all the hydrogen atoms and the missing side chains of residues whose backbone coordinates were observed in the structure. The orientation of polar hydrogens was optimized, the protein protonation states were adjusted
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The SiteMap tool of the Schrödinger suite was used to identify potential binding sites in the structures. Molecular docking of PSB-0413 at the agonist-bound P2Y 12 R crystal and at the P2Y 12 Gln-187 variant models was performed by means of the Glide package 24 from the Schrödinger suite. 23 In particular, a Glide Grid was centered on the centroid of residues located within 6 Å from the previously identified cavity. The Glide Grid was built using an 
Results
Studies in patient III-7 (propositus)
Platelet aggregation and secretion
The platelets from patient III-7 changed shape normally following stimulation with 1 μM ADP (not shown) and underwent aggregation in response to 4-20 μM ADP that was markedly lower than normal and rapidly reversible (Figure 2 ). The aggregation of these platelets in response to other platelet agonists was normal (not shown). Very similar results were obtained in experiments performed in Freiburg ( Figure 2 ) and in Milan (not shown). The ATP secretion from patient platelets was absent after stimulation by ADP, and normal after stimulation by other agonists (Table 1) .
For
Binding of fluorescein-conjugated fibrinogen to ADP-activated platelets
Compared to healthy controls, the amount of fluorescein-conjugated fibrinogen bound to platelets upon stimulation with ADP (0.25-2.0 µmol/L) was severely impaired (Figure 3) .
Inhibition of PGE 1 -induced increase in platelet cAMP
The basal level of platelet cAMP was normal (12.2 pmoles/10 9 platelets; normal range: 6-17.9) and normally increased about 10-fold after stimulation with 1 μM PGE 1. ADP, in a concentration-dependent manner, inhibited the production of cAMP by normal platelets exposed to PGE 1 , but this response was greatly impaired in the patient´s platelets (Table   2 ). In contrast to ADP, epinephrine normally inhibited the production of cAMP in patient's platelets exposed to PGE 1 ( Table 2 ), suggesting that the defect could be attributed to an abnormality in the platelet P2Y 12 R responsible for specifically coupling ADP stimulation to adenylyl cyclase inhibition.
VASP phosphorylation assay
The PRI value of patient's platelets was 30% in an experiment done in Milan and 1% in a subsequent experiment done in Freiburg, compared to 78.7±6.7% in platelets from 31 normal subjects. The number of binding sites/platelet (Bmax) was comparable between normal and patient platelets (Table 3) ; however, the K D values were higher with patient platelets than with normal platelets (Table 3) .
Binding of [ 3 H]PSB-0413 to washed platelet suspensions
Characterization of the P2Y 12 R gene
The observation that the patient platelets had a normal number of binding sites for [ 3 H]PSB-0413 in spite of a severely impaired function of the P2Y 12 R suggested that a dysfunctional receptor was being synthesized in normal amounts. To identify the underlying structural changes, we analyzed the coding sequence of P2Y 12 R from DNA fragments generated in a PCR reaction. DNA from the patient showed a homozygous c.847T>A substitution that changed the codon for His-187 to Gln (p.His187Gln), located in the TM5 portion of the receptor.
Family studies
For 11 of 20 first-and second-degree relatives of the propositus, it was possible to retrieve information on the individual bleeding history and blood samples for DNA extraction and genotyping. Seven subjects (the grandparents, the parents, 2 sisters and 1 brother) were heterozygous for p.His187Gln; one brother and 2 sisters had wild-type P2Y 12 R and 1 brother had homozygous p.His187Gln. The bleeding history was negative in all subjects, except in 2 sisters (1 with heterozygous p.His187Gln 
Molecular modeling studies
To predict the implications of the p.His187Gln substitution at a molecular level, we performed molecular modeling studies of the P2Y 12 R. Two recently published crystallographic structures of the human P2Y 12 R, 12, 13 in complex with both agonist and antagonist, resulted to be very useful for this study. Moreover, models of the P2Y 12 R p.His187Gln variant were built using the agonist-bound P2Y 12 R crystal structure, to analyze the possible structural differences due to this sequence variation.
TM5 in both P2Y 12 R crystal structures is unusually straight and tilted, because of the absence of proline (e.g. position 5.50 following the Ballesteros-Weinstein numbering system), 25 or glycine residues in this helix in other GPCRs that destabilize its straight (2.60), Arg93 (3.21), Arg256 (6.55), Tyr259 (6.58) and Lys280 (7.35).
When docked at the P2Y 12 R p.His187Gln variant models, PSB-0413 showed the same orientation in the binding site and similar interactions as in the WT receptor (data not shown). However, depending on the rotamer of the side chain of Gln187, the H-bonding network involving the 2'-hydroxyl group can differ. In fact, in some rotamers Gln187 does 
Discussion
Congenital defects and pharmacological inhibition of the P2Y 12 R for ADP are associated with an increased bleeding risk, demonstrating the important role of this receptor in platelet function and normal hemostasis. 26 Most of the congenital defects of P2Y 12 R characterized to date are associated with a marked decrease of the platelet binding sites for ADP, which has been attributed to mutations that disrupt the synthesis of the receptor, 2,26-30, to alterations in the ligand binding site 10 , or to compromised P2Y 12 R recycling. 14 A recently described patient displayed abnormalities in P2Y 12 R signalling, traffic and surface expression, which was associated with the substitution of Arg122 with a cysteine. 31 In one kindred, a case of a normal expression of the receptor that was associated with severely defective signal transduction was described. 7 Nucleotide sequence analysis of the P2Y 12 gene revealed that the patient was a compound heterozygote for two missense mutations that caused the substitution p.Arg256Gln (in TM6) and p.Arg265Trp (in EL3), suggesting that the structural integrity of TM6 and EL3 regions is necessary for normal receptor function. A heterozygous mutation in the same region of the molecule, p.Pro258Thr, was later described in a patient with mild bleeding disorder and severely impaired ADP-induced platelet aggregation, confirming that this region of the molecule is important for receptor function. 8 The recently reported crystallographic data for the human P2Y 12 R support these findings revealing that significant conformational changes occur in the TM6-EL3 region between the agonist-and antagonist-bound structures. 12, 13 For
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In the present report, we describe the case of a patient and his brother with lifelong bleeding disorder associated with defective P2Y 12 R-dependent platelet function, associated with normal expression of the receptor but decreased affinity for its ligand. These experiments were performed using the light transmission aggregometer APACT 4 (Labor Fibrintimer, Ahrensburg, Germany). 
